Crescita Therapeutics Management
Management criteria checks 2/4
We currently do not have sufficient information about the CEO.
Key information
Serge Verreault
Chief executive officer
CA$462.3k
Total compensation
| CEO salary percentage | 81.1% |
| CEO tenure | 7.1yrs |
| CEO ownership | 3.8% |
| Management average tenure | no data |
| Board average tenure | 8.2yrs |
Recent management updates
Recent updates
Why Investors Shouldn't Be Surprised By Crescita Therapeutics Inc.'s (TSE:CTX) 33% Share Price Surge
Jan 04
Is Crescita Therapeutics (TSE:CTX) Using Debt Sensibly?
Nov 18Increases to CEO Compensation Might Be Put On Hold For Now at Crescita Therapeutics Inc. (TSE:CTX)
May 05Crescita Therapeutics Inc.'s (TSE:CTX) Stock On An Uptrend: Could Fundamentals Be Driving The Momentum?
Feb 10
CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Dec 31 2023 | CA$462k | CA$375k | -CA$2m |
| Sep 30 2023 | n/a | n/a | -CA$658k |
| Jun 30 2023 | n/a | n/a | CA$819k |
| Mar 31 2023 | n/a | n/a | CA$1m |
| Dec 31 2022 | CA$704k | CA$375k | CA$862k |
| Sep 30 2022 | n/a | n/a | CA$627k |
| Jun 30 2022 | n/a | n/a | -CA$468k |
| Mar 31 2022 | n/a | n/a | -CA$1m |
| Dec 31 2021 | CA$651k | CA$375k | -CA$1m |
| Sep 30 2021 | n/a | n/a | -CA$3m |
| Jun 30 2021 | n/a | n/a | CA$2m |
| Mar 31 2021 | n/a | n/a | CA$95k |
| Dec 31 2020 | CA$659k | CA$338k | CA$37k |
| Sep 30 2020 | n/a | n/a | CA$146k |
| Jun 30 2020 | n/a | n/a | -CA$4m |
| Mar 31 2020 | n/a | n/a | CA$1m |
| Dec 31 2019 | CA$823k | CA$336k | CA$2m |
| Sep 30 2019 | n/a | n/a | CA$5m |
| Jun 30 2019 | n/a | n/a | CA$6m |
| Mar 31 2019 | n/a | n/a | CA$3m |
| Dec 31 2018 | CA$555k | CA$287k | CA$2m |
| Sep 30 2018 | n/a | n/a | -CA$9m |
| Jun 30 2018 | n/a | n/a | -CA$10m |
| Mar 31 2018 | n/a | n/a | -CA$9m |
| Dec 31 2017 | CA$734k | CA$173k | -CA$11m |
Compensation vs Market: Serge's total compensation ($USD337.99K) is above average for companies of similar size in the Canadian market ($USD174.43K).
Compensation vs Earnings: Serge's compensation has been consistent with company performance over the past year.
CEO
Serge Verreault
7.1yrs
Tenure
CA$462,268
Compensation
Mr. Serge Verreault, BA, MBA has been the President of Crescita Therapeutics Inc. since April 17, 2017 and its Chief Executive Officer since April 2, 2018 and is Director from June 20, 2023. Mr. Verreault...
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| President | less than a year | CA$462.27k | 3.81% CA$ 319.0k | |
| Independent Lead Director | 8.2yrs | CA$74.75k | 0.51% CA$ 43.0k | |
| Independent Vice Chairman | 8.2yrs | CA$60.75k | 0.99% CA$ 83.2k | |
| Non-Executive Chairman | 8.2yrs | CA$72.25k | 5.43% CA$ 454.7k | |
| Independent Non-Executive Director | 2.5yrs | CA$56.75k | no data |
8.2yrs
Average Tenure
Experienced Board: CTX's board of directors are considered experienced (8.2 years average tenure).